Concise overview articles of key topics in neurodegeneration, which can be read wherever you are, whenever suits you.
Find out more here.
Announcing the launch of Mini Reviews
New Thematic Series - AI in Dementia
Alzheimer's Research & Therapy presents a thematic series focusing on the use of artificial intelligence, machine learning and related techniques in dementia research.
Find out more about the series here.
Articles
-
-
How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment
-
Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
-
Exploring shared neural substrates underlying cognition and gait variability in adults without dementia
-
Understanding factors associated with the trajectory of subjective cognitive complaints in groups with similar objective cognitive trajectories
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
-
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:70
Early Career Researcher Reviewer Panel
Interested in an introduction to peer reviewing articles for Alzheimer's Research & Therapy?
Find out more about our ECR Peer Reviewer Panel!
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Published Thematic Series
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Alzheimer's blogs from BMC
Failed to load RSS feed.
Affiliated with
Annual Journal Metrics
-
2022 Citation Impact
9.0 - 2-year Impact Factor
9.2 - 5-year Impact Factor
1.849 - SNIP (Source Normalized Impact per Paper)
2.650 - SJR (SCImago Journal Rank)2022 Speed
7 days submission to first editorial decision for all manuscripts (Median)
134 days submission to accept (Median)2022 Usage
1,519,569 downloads
9,465 Altmetric mentions